Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004050 · ClinicalTrials.gov registry record · Phase 2
Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
A Phase 2 study, sponsored by Vical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00004050: Clinical Trial Phase 2 study, sponsored by Vical.
NCT00004050 is a Phase 2 study that was terminated before completion, run by Vical. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004050, a Phase 2 study, was terminated before completion, sponsored by Vical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Inserting the gene for interleukin-2 into a person's cancer cells may improve the body's ability to fight cancer. Using Leuvectin to deliver this gene may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of Leuvectin followed by surgery in treating patients who have stage II or stage III prostate cancer.
Primary Outcome
Measure timing and rate of disease recurrence
Interventions
- BIOLOGICAL Leuvectin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1999-06 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
Why NCT00004050 stopped before completion
NCT00004050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Leuvectin is the first listed.
NCT00004050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004050 about?
NCT00004050 is a clinical study titled "Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer". RATIONALE: Inserting the gene for interleukin-2 into a person's cancer cells may improve the body's ability to fight cancer. Using Leuvectin to deliver this gene may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of Leuvectin followed by surgery in...
What is the current status of trial NCT00004050?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 1999-06. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00004050?
The interventions under investigation include: Leuvectin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004050?
This trial is sponsored by Vical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004050's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia